ABBV AbbVie Inc.

80.02
+1.27  (+2%)
Previous Close 78.75
Open 79.16
Price To Book -41.25
Market Cap 120367390487
Shares 1,504,216,327
Volume 5,003,700
Short Ratio 2.98
Av. Daily Volume 7,251,786

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be initiated 1H 2018.
Risankizumab
Ulcerative colitis
Phase 1 data at ASCO. Oral Abstract 2003. June 4, 2017.
ABT-414
Recurrent glioblastoma (rGBM)
Phase 3 trial did not meet primary endpoints - April 19, 2017.
Veliparib
Squamous non-small cell lung cancer (NSCLC) and triple negative breast cancer (TNBC)
Approved November 13, 2013.
Ibrutinib
Relapsed or refractory MCL mantle cell lymphoma
Approved February 12, 2014.
Imbruvica
Cancer - Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy
Approved July 19, 2014.
Imbruvica
Deletion 17p
Approved December 19, 2014.
VIEKIRA PAK
HCV - genotype 1
Approved January 29, 2015 - PCYC
IMBRUVICA
Waldenström’s Macroglobulinemia
Phase 2 initiation announced January 25, 2017.
ABBV-8E12
Progressive supranuclear palsy (PSP)
Phase 2 initiation announced January 25, 2017.
ABBV-8E12
Alzheimer's disease
Approval announced June 11, 2018.
Venclexta (MURANO)
Relapsed or refractory Chronic Lymphocytic Leukemia (CLL)
Phase 3 trial initiated July 2016.
Venetoclax
Relapsed or refractory multiple myeloma
Phase 3 trial planned.
Venclexta
First-line Diffuse large B-cell lymphoma (DLBCL)
Phase 3 trial planned.
Venclexta
Follicular lymphoma (FL)
Phase 3 trial to commence 2H 2017.
Risankizumab
Crohn’s Disease
BLA filing announced April 25, 2018. PDUFA estimate April 24, 2019.
Risankizumab
Psoriasis
Approval announced August 2, 2017.
Imbruvica
Second-line Chronic graft-versus-host disease (GVHD)
Phase 3 trial to commenced 2017.
ABT-494
Psoriatic Arthritis
Phase 3 trial planned for 2018.
Risankizumab
Psoriatic Arthritis
Phase 3 trial initiated late 2017.
ABT-494
Crohn’s Disease
Phase 2 pivotal data released March 22, 2018. ORR of 16% + overall survival 5.6 months noted. Abstract 8507.
Rova-T (TRINITY)
Third-line Small Cell Lung Cancer
Phase 2b data released September 7, 2017 - primary endpoint met. Phase 3 trial to be initiated 1H 2018.
ABT-494
Atopic Dermatitis
sNDA filing announced September 26, 2017. Priority Review. Approved January 19, 2017.
Imbruvica
Marginal zone lymphoma
Approval announced August 3, 2017.
Glecaprevir/Pibrentasvir (G/P)
Hepatitis C virus (HCV)
NDA filing due 2019.
Elagolix
Uterine Fibroids
FDA approval announced July 24, 2018.
Elagolix
Endometriosis
PDUFA date under priority review estimated at August 19, 2019.
ABT-494 upadacitinib
Rheumatoid arthritis
Phase 3 enrolment to be stopped due to shorted overall survival following recommendation from Independent Data Monitoring Committee (IDMC) December 5, 2018.
Rova-T (TAHOE)
Second-line Small Cell Lung Cancer
Phase 3 data due 2020.
Rova-T (MERU)
First-line Small Cell Lung Cancer
FDA approval announced January 28, 2019.
Imbruvica and Gazyva - iLLUMINATE
Chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL)
FDA approval announced August 27, 2018.
IMBRUVICA (ibrutinib)
Waldenström’s Macroglobulinemia
Phase 3 trial did not meet primary endpoint - noted July 11, 2018.
IMBRUVICA (ibrutinib)
Diffuse large B-cell lymphoma (DLBCL)
FDA approval announced November 21, 2018.
Venclexta
First line unfit AML
Phase 2b data released October 22, 2018 - primary endpoint met. Phase 3 trial initiation announced October 2018.
Upadacitinib - U-ACHIEVE
Ulcerative colitis
Phase 3 data released October 31, 2018 - PFS primary endpoint met.
Venetoclax
Chronic Lymphocytic Leukemia
Phase 3 primary endpoint not met (PFS/OS).
Ibrutinib (Imbruvica)
Pancreatic cancer
Phase 3 data due 2019.
Venclexta plus Gazyva
Chronic lymphocytic leukemia (CLL)
Phase 3 data due 2019.
Venclexta MIRROS
Acute myeloid leukemia (AML)
Phase 3 data due 2019.
Venclexta BELLINI
Multiple myeloma

Latest News

  1. Why Voyager Therapeutics Is Skyrocketing Today
  2. Voyager Therapeutics stock jumps on 2nd Parkinson's deal
  3. What Are the Key Growth Catalysts for AbbVie in 2019?
  4. Voyager Shares Take Off on Parkinson's Disease Development Deal
  5. Pharma Stock Roundup: MRK Buys IMDZ, FDA Grants Priority Review to Some Candidates
  6. Comparing Dividends and Interest Expenses for GILD and ABBV
  7. Voyager Therapeutics stock soars after AbbVie collaboration potentially valued at over $1 billion
  8. AbbVie and Voyager Therapeutics Announce Collaboration to Develop Vectorized Antibodies to Treat Parkinson's Disease and Other Synucleinopathies
  9. GILD or ABBV: Which Is Controlling Its Expenses Better?
  10. What Pharma Investors Need to Know About Pfizer's Latest Disaster
  11. GILD or ABBV: Which Is Expected to Report Faster EPS Growth?
  12. AbbVie Declares Quarterly Dividend
  13. What Analysts Are Recommending for GILD and ABBV in February
  14. The Daily Biotech Pulse: Genomic Health Earnings, AbbVie's Humira Approved For Another Indication In Japan
  15. Waltham biotech Morphic signs $725M partnership with Janssen
  16. AbbVie's RA Candidate Upadacitinib Gets FDA Priority Review
  17. U.S. settles with Teva over keeping generic drugs off market
  18. Roche's (RHHBY) BLA for Lymphoma Drug Gets Priority Review
  19. 2 Pharma Stocks in the Middle of an Oncology Sales Explosion
  20. AbbVie stock up 0.2% after FDA grants upadacitinib priority review status